APOTHEEK OOSTERLYNCK

Active

Public limited companyfounded 1992active for 34 yearsBrugsesteenweg 239-241, 8800 Roeselare, BelgiumKBO/BCE: BE 0446.267.306

From the official registers: KBO 34 annual accounts at the National Bank publications in the Belgian Official Gazette

Summary

APOTHEEK OOSTERLYNCK has been active since 1992 and the Belgian Official Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €1.0m and a net result of €84,104. Equity has been shrinking by about 5.2% per year since 2018. Its solvency ranks better than 66% of 5,036 sector peers (NACE 47, financial year 2025). The computed 12-month bankruptcy probability is 0.1% (very low).

Risk analysisFollow Report Compare

APOTHEEK OOSTERLYNCKActiveChecked score 95/100

Risk analysis Report Compare

Official details

KBO

Status: Active since 17-01-1992 Normal situation
Legal form: Public limited company
Registered office: Brugsesteenweg 239-241, 8800 Roeselare
Activity: Retail sale of pharmaceutical products NACE 47730
Establishment unit: 2.056.564.702 8800 Roeselare, since 11-03-1992
Financial year end: 31 December
Peppol: Reachable since 19-02-2026

Company details

Board and ownership

Board

VASTGOED, BEHEER EN PATRIMONIUMManaging director · permanent representative OOSTERLYNCK Jeroen
PARK KYUNG SOODirector

Board & ownership

Financial position

95 Excellent Checked score 2025

Bankruptcy probabilitywithin 12 months: 0.1%

Annual accounts 2025

Gross margin: €257,975; ▼ 14.6%
Turnover: ≈ €940,000; estimated
Profit: €84,104; ▼ 44.2%
Equity: €1.0m; ▲ 8.9%
Total assets: €2.0m; ▲ 1.5%
Staff: 2.1 FTE; ▲ 40.0%

2025 accounts filed 53 days after the deadline

Filed on 22-09-2026at the National Bank

Financials

Score breakdownraises riskLast filed accounts filed 53 days late; 2 of the last 3 accounts latelowers riskLiquidity: current ratio 1.91, cash €937,821Size: 2.1 FTE, total assets €2.0mFounded in 1992Show the evidence

Checked score

Score 2025

95 / 100

Excellent

Probability in this band: under 0.55%

Financially stronger than 63% of micro companies in retail trade (NACE 47)

Every signal that counts is listed under Signals.

Financial strength · tick: 2024

Strong

Solvency 76+4

equity 50.9% of total assets

Liquidity 76+3

short-term debt 49.1% · cash 46.6%

Profitability 68-10

return on assets 4.2%

Bankruptcy probability within 12 months

0.1% Very low

0%0.5%1.5%4%10%≥ 25%

Fewer than 1 in 1,000 comparable companies go bankrupt within 12 months (an estimate).

Sector median 0.6% (40,270 companies, NACE 47, micro)

Last 24 months 11-2024: 0.1% 12-2024: 0.1%● unchanged vs 11-2024 01-2025: 0.1%● unchanged vs 12-2024 02-2025: 0.1%● unchanged vs 01-2025 03-2025: 0.1%● unchanged vs 02-2025 04-2025: 0.1%● unchanged vs 03-2025 05-2025: 0.1%● unchanged vs 04-2025 06-2025: 0.1%● unchanged vs 05-2025 07-2025: 0.1%● unchanged vs 06-2025 08-2025: 0.3%▲ +0.2 percentage points vs 07-2025highest value 09-2025: 0.1%▼ -0.2 percentage points vs 08-2025 10-2025: 0.1%● unchanged vs 09-2025 11-2025: 0.1%● unchanged vs 10-2025 12-2025: 0.1%● unchanged vs 11-2025 01-2026: 0.1%● unchanged vs 12-2025 02-2026: 0.1%● unchanged vs 01-2026 03-2026: 0.1%● unchanged vs 02-2026 04-2026: 0.1%● unchanged vs 03-2026 05-2026: 0.1%● unchanged vs 04-2026 06-2026: 0.1%● unchanged vs 05-2026lowest value 07-2026: 0.1%● unchanged vs 06-2026 08-2026: 0.2%▲ +0.1 percentage points vs 07-2026 09-2026: 0.2%● unchanged vs 08-2026 10-2026: 0.1%▼ -0.1 percentage points vs 09-2026

Credit of up to €95,000 on 30-day terms is acceptable

Liquidity is ample, with a current ratio of 1.91 (1.76 in 2024), above the usual 1.5. Short-term debt is 49.1% and cash 46.6% of total assets. 49.1% of the assets are financed with debt and provisions.

Calculation

The band follows from the bankruptcy probability. 10 more points roughly halve it.

75-100	Excellent	under 0.55%
60-74	Healthy	0.55% to 1.5%
45-59	Fair	1.5% to 4.2%
25-44	Weak	4.2% to 15.0%
0-24	Critical	over 15.0%

Where the company stands within its band depends half on the bankruptcy probability and half on how it does against its sector peers (NACE 47, micro). It does better than 65% of them on solvency, 81% on liquidity, 48% on profitability and 59% on growth.

The bankruptcy probability was computed on 31-10-2026 by the bankruptcy model of 2 October 2026, which learns from Belgian bankruptcies and reads the registers, the annual accounts and the Belgian Official Gazette.

Some facts cap the score, however low the probability. With negative or zero equity, a heavy loss, a special status in the KBO, one missing filing or accounts filed more than 90 days late, the score is Fair at most (59). With two missing filings, it is Weak at most (44). During a judicial reorganisation or at the company's end (bankruptcy, dissolution, liquidation), it is Critical at most (24).

Credit check for an amount and term of your choice

Show the recommended maximum and see how the verdict changes with amount, term and advance.

Signals

Six signals.

lowers riskraises risk

Last filed accounts filed 53 days late; 2 of the last 3 accounts late

NBB · filings

Liquidity: current ratio 1.91, cash €937,821

NBB · annual accounts

Size: 2.1 FTE, total assets €2.0m

Companies of this size fail less often. How much that weighs depends on the rest of the company's profile.

NBB · annual accounts

Founded in 1992

Companies that have existed this long fail less often. How much that weighs depends on the rest of the company's profile.

KBO

Growing equity

Reported equity is higher than in 2023 and did not fall compared with 2024. These amounts do not establish the cause of the change.

NBB · annual accounts 2025

Equity per financial year

1819202122232425

2018 to 2025 · latest year €1.0m

2025 accounts filed 53 days late

The financial year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 22-09-2026, 53 days later. Nearly half (47%) of Belgian companies file late; of those that file 1 to 90 days late, 2.0% are now bankrupt, dissolved or in another special legal status, against 1.66% of all filers. A delay like this does not count in the score.

NBB · 10 filings

Deviation from the deadline

2025

53 days late

2024

28 days late

2023

49 days late

2022

66 days late

2021

74 days late

2020

88 days late

2019

54 days late

← before the deadline after the deadline →

tick = median of all Belgian filingsring = median in the sector

The company filed its last 7 accounts on average 59 days after the deadline. In the sector (NACE 47), the median for financial year 2024 was on the deadline day, and 47% of those companies filed late.

Searched, nothing found (2)

Next filing not due yet

The next financial year closes on 31-12-2026 and is due by 31-07-2027. Nothing is late today. The company usually files around 22 September (5 of the last 5 filed years within 30 days of that day).

Companies Code · seven months

Where today falls in the filing period

01-11-2026 today31-12-2026 year end31-07-2027 deadline

No strike-offs in the KBO publications

That holds for every publication since 2021.

KBO publications

Key points

Caution: Result fell in 2025from €150,653 to €84,104 ▼ 44.2% View
Positive: 8 profitable years in a rowprofit 2025: €84,104 8 years View

Documents

Key facts about APOTHEEK OOSTERLYNCK

What is the company number of APOTHEEK OOSTERLYNCK?: The company number of APOTHEEK OOSTERLYNCK is 0446.267.306. The VAT number is the same number with BE in front: BE 0446.267.306.
Where is APOTHEEK OOSTERLYNCK based?: The registered office is at Brugsesteenweg 239-241, 8800 Roeselare.Company details
What does APOTHEEK OOSTERLYNCK do?: According to the KBO register, the main activity is retail sale of pharmaceutical products (NACE 47730).
What is the legal form of APOTHEEK OOSTERLYNCK?: The legal form of APOTHEEK OOSTERLYNCK is Public limited company (NV).
When was APOTHEEK OOSTERLYNCK founded?: APOTHEEK OOSTERLYNCK was founded on 17-01-1992.
Is APOTHEEK OOSTERLYNCK still active?: Yes, APOTHEEK OOSTERLYNCK is an active enterprise in the KBO register.
How many employees does APOTHEEK OOSTERLYNCK have?: APOTHEEK OOSTERLYNCK had an average of 2.1 full-time equivalents in financial year 2025, according to the filed annual accounts.Financials
What is the turnover of APOTHEEK OOSTERLYNCK?: The turnover in financial year 2025 is ≈ €940,000. This figure is estimated from the gross margin of €257,975 and 47 comparable companies (NACE 477). It probably lies between €730,000 and €1.5m.
Is APOTHEEK OOSTERLYNCK profitable?: In financial year 2025, APOTHEEK OOSTERLYNCK made a profit of €84,104.
Where can I find the annual accounts of APOTHEEK OOSTERLYNCK?: APOTHEEK OOSTERLYNCK filed 34 annual accounts with the National Bank of Belgium, the latest for financial year 2025.Annual accounts at the National Bank
When are the next annual accounts of APOTHEEK OOSTERLYNCK due?: APOTHEEK OOSTERLYNCK must file the annual accounts for financial year 2026 by 31-07-2027.Timeline

Comparable companies

These companies have the same main activity as APOTHEEK OOSTERLYNCK: retail sale of pharmaceutical products (NACE 47730). They are comparable in size and age: total assets between €1.6m and €2m, founded between 1982 and 1994.

Company	Total assets	Gross margin
APOTHEEK OOSTERLYNCK Roeselare	€2.0m	€0.3m
APOTHEEK VAN OVERBERGE Gistel	€1.8m	€0.2m
APOTHEEK DIRK VAN HERCK Nijlen	€1.8m	€0.2m
Apotheek Luyten Nijlen	€1.8m	€0.3m
APOTHEEK SINT-JOZEF Olen	€1.6m	€0.2m
APOTHEEK GODERIS & VINCENT Staden	€2.0m	€0.3m
Apotheek Rogge Damme	€1.6m	€0.3m